×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
复旦大学上海医学院 [9]
中国医学科学院 北京... [4]
内容类型
会议论文 [8]
期刊论文 [5]
发表日期
2017 [1]
2016 [4]
2015 [7]
2014 [1]
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共13条,第1-10条
帮助
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study
期刊论文
2017, 卷号: 113, 页码: 37-44
作者:
Han, Baohui
;
Tjulandin, Sergei
;
Hagiwara, Koichi
;
Normanno, Nicola
;
Wulandari, Laksmi
收藏
  |  
浏览/下载:4/0
  |  
提交时间:2020/01/03
Adenocarcinoma
Circulating free tumour-derived DNA
Diagnostic
Epidermal growth factor receptor
Non-small-cell lung cancer
Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT.
会议论文
作者:
Peeters, Marc
;
Kim, Tae Won
;
Li, Jin
;
Cascinu, Stefano
;
Ruff, Paul
收藏
  |  
浏览/下载:5/0
  |  
提交时间:2019/12/05
Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer
期刊论文
EUROPEAN JOURNAL OF CANCER, 2016, 卷号: 68
作者:
Price, Timothy
;
Kim, Tae Won
;
Li, Jin
;
Cascinu, Stefano
;
Ruff, Paul
收藏
  |  
浏览/下载:6/0
  |  
提交时间:2019/12/06
Anti-EGFR therapy
Colorectal cancer
Gastrointestinal cancer
Panitumumab
Outcomes by hypomagnesemia (hypomag) in the randomized phase III ASPECCT trial of patients (pts) with chemofractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC).
会议论文
作者:
Peeters, Marc
;
Kim, Tae Won
;
Li, Jin
;
Cascinu, Stefano
;
Ruff, Paul
收藏
  |  
浏览/下载:7/0
  |  
提交时间:2019/12/06
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
期刊论文
2016, 卷号: 34, 期号: 10, 页码: 1034-+
作者:
Piccart-Gebhart, Martine
;
Holmes, Eileen
;
Baselga, Jose
;
de Azambuja, Evandro
;
Dueck, Amylou C.
收藏
  |  
浏览/下载:10/0
  |  
提交时间:2020/01/04
Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).
会议论文
作者:
Price, Timothy Jay
;
Newhall, Kathryn
;
Peeters, Marc
;
Kim, Tae Won
;
Li, Jin
收藏
  |  
浏览/下载:2/0
  |  
提交时间:2019/12/13
Randomized phase 3 study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): outcomes by hypomagnesemia (hypomag) in ASPECCT
会议论文
作者:
Peeters, Marc
;
Price, Timothy Jay
;
Kim, Tae Won
;
Li, Jin
;
Cascinu, Stefano
收藏
  |  
浏览/下载:3/0
  |  
提交时间:2019/12/13
Randomized phase III study of panitumumab (pmab) vs. cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): Outcomes by hypomagnesemia (hypomag) in ASPECCT.
会议论文
作者:
Price, Timothy Jay
;
Peeters, Marc
;
Kim, Tae Won
;
Li, Jin
;
Cascinu, Stefano
收藏
  |  
浏览/下载:5/0
  |  
提交时间:2019/12/13
Final results from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC)
会议论文
作者:
Price, Timothy Jay
;
Peeters, Marc
;
Kim, Tae Won
;
Li, Jin
;
Cascinu, Stefano
收藏
  |  
浏览/下载:7/0
  |  
提交时间:2019/12/13
Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).
会议论文
作者:
Price, Timothy Jay
;
Newhall, Kathryn
;
Peeters, Marc
;
Kim, Tae Won
;
Li, Jin
收藏
  |  
浏览/下载:3/0
  |  
提交时间:2019/12/19
©版权所有 ©2017 CSpace - Powered by
CSpace